• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TNFA

    TNF Pharmaceuticals Inc.

    Subscribe to $TNFA
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    IPO Year: 2014

    Exchange: NASDAQ

    Recent Analyst Ratings for TNF Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    TNF Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vice President, Finance Rauch Gary M

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:15 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by President, CMO Glass Mitchell

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:12 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Interim CFO Rhodes Ian

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:14 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. SEC Filings

    View All

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    9/26/25 5:10:36 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/10/25 5:00:34 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/5/25 5:30:47 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form D filed by TNF Pharmaceuticals Inc.

    D - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/5/25 5:30:17 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/2/25 9:29:14 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by TNF Pharmaceuticals Inc.

    10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    8/19/25 5:15:52 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form NT 10-Q filed by TNF Pharmaceuticals Inc.

    NT 10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    8/14/25 5:01:51 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    6/6/25 5:00:39 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form DEFR14A filed by TNF Pharmaceuticals Inc.

    DEFR14A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    5/19/25 5:26:41 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by TNF Pharmaceuticals Inc.

    10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    5/15/25 4:15:59 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TNF Pharmaceuticals Inc.

    SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)

    11/14/24 2:24:58 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. Financials

    Live finance-specific insights

    View All

    TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

    Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company's lead candidate isomyosamine, a novel oral TNF

    3/5/25 9:00:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"

    Licensed technology positions Company at forefront of new quantum-class computing paradigm Q/C Technologies, Inc. (NASDAQ:QCLS), formerly TNF Pharmaceuticals, Inc. (NASDAQ: TNFA), ("Q/C" or "the Company"), today announced that its common stock will begin trading under the new ticker symbol "QCLS" beginning today at the market open. The Company's new name Q/C Technologies represents its recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver's light-speed laser processing unit (LPU), the world's first light and laser-based computing system, for application in quantum class cryptocurrency verticals. "The official transition to Q/C Technologies and

    9/25/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing

    New trading symbol QCLS effective Thursday, September 25, 2025 Licensed technology positions Company at forefront of new quantum-class computing paradigm TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("Q/C" or the "Company") today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol "QCLS" on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol "TNFA." The new name Q/C Technologies represents the Company's recent strategic pivot into quantum-class computing with exclusive global rights to

    9/24/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

    TNF Pharmaceuticals Inc. (NASDAQ:TNFA), ("TNF" or the "Company") today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have regained compliance with Nasdaq's listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. We will be updating shareholders on our progress in the weeks ahead,"

    9/17/25 9:24:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    Management to present on Wednesday, September 10, 2025, at 8:00 a.m. ET TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced its participation in the H.C. Wainwright & Co. 27th Annual Global Investment Conference taking place September 8–10, 2025, at the Lotte New York Palace Hotel in New York City. TNF's presentation is scheduled for Wednesday, September 10, 2025, at 8:00 a.m. ET. Presentation Details: Date and time: September 10, 2025, at 8:00 a.m. ET1 Location: Lotte New York Palace Hotel, New York City, Rutherford Room, 4th Floor Conference registration: hcwevents.com/annualconference In addition to th

    9/8/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Announces Closing of $7 Million Private Placement

    Financing priced at a 44% premium to market Led by a top strategic investor with significant participation from existing stockholders TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced the closing of a $7.0 million private placement financing of convertible preferred stock with the Company's largest strategic stockholder and other existing stockholders. The private placement involved the sale of 7,000 shares of preferred stock, with a stated value of $1,000 per share, convertible into 1,400,000 million shares of the Company's common stock at an initial conversion price of $5.00, and accompanying warrants to purchase up to 1,400,000 shares of the Company's

    9/4/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

    TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announced that it has increased its stake in TNF Pharmaceuticals (NASDAQ:TNFA, "TNF")) by an additional $3 million. The Company does so to help support TNF's recent acquisition of a license with LightSolver, Ltd. ("LightSolver"), a company recognized by Gartner and the World Economic Forum for its breakthrough innovations. The license is for its revolutionary processing accelerator designed to expedite compute-sensitive computations by

    9/2/25 9:20:00 AM ET
    $PMCB
    $TNFA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications

    First light- and laser-based computing system designed to outperform quantum and supercomputing and solve complex problems unfeasible for GPUs Strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recognized in Gartner's 2025 Hype Cycle for Data Center Infrastructure Technologies Supported by strategic investment from TNF's largest stockholder; TNF to pursue name change reflecting new direction TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company") today announced that it has entered into a licensing agreement for an innovative processing accelerator designed to expedite compute-intensive computations In partnership with LightSolver Ltd. ("Li

    9/2/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance

    TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that its board of directors has authorized a reverse stock split of the Company's common stock at a ratio of 1 post-split share for every 100 pre-split shares. The Company's common stock will begin trading on a split-adjusted basis upon market open on Tuesday, September 2, 2025. The Company expects to provide operational business updates coinciding with the completion of the reverse stock split. The new CUSIP number for the Company's common stock following the reverse stock split i

    8/28/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation

    Transforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. "The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value

    8/19/25 5:20:00 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

    Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a nonprofit organization seeking innovative ways to accelerate research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). Together, the parties are expected to initiate a Compassionate Use (Expanded Access) study evaluating TNF's lead candidate isomyosamine as a potential trea

    6/24/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care